Univar Announces Distribution Agreement with Swati Spentose for Lidocaine Products
News Oct 23, 2013
Univar is announcing the partnership at CPhl Worldwide Oct. 22 – 24 in Frankfurt, Germany, where it will be showcasing its pharmaceutical portfolio and technical expertise.
The agreement with Swati Spentose Pvt. Ltd. includes distribution in the United States and Puerto Rico for both Lidocaine Base and Lidocaine HCl. The products are used in a variety of anaesthetic and antiarrhythmic applications in the form of topical, oral, transdermal and injectable products.
“We are very excited to begin this relationship with Swati Spentose,” said Tom Nist, Univar USA Director of Pharmaceutical Ingredients. “The combined manufacturing expertise from Swati Spentose and Univar’s marketing and sales capabilities offers customers greater access to these active pharmaceutical ingredients (API). The Lidocaine Base and Lidocaine HCl are excellent additions to Univar’s API portfolio.”
Univar’s offering to pharmaceutical manufacturers extends beyond traditional technical and formulation support. It includes detailed insight into the industry’s market trends and complex regulatory demands, including stringent quality control and services such as change control management.
“As part of our ongoing commitment to world class manufacturing, we are focused on partnering with companies across the value chain to provide the most comprehensive service to our customers,” said Swati Jajodia, CEO, Swati Spentose Pvt. Ltd. “Univar’s extensive distribution network and commitment to safety, makes it an excellent partner to help us reach more customers with our lidocaine products.”
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018